AVT Natural Products Limited Overview
AVT Natural Products is a small-cap, export-oriented Indian maker of plant-derived ingredients, and part of the Chennai-based A.V. Thomas Group. Its main businesses are:
-
Marigold extracts (lutein and xanthophylls) for eye-health nutraceuticals, food colour and poultry pigmentation
-
Spice oils and oleoresins (paprika, capsicum, pepper and others)
-
Value-added teas (decaffeinated and instant/soluble)
-
A smaller but fast-growing line of botanical animal health and nutrition products
The model is backward-integrated in marigold. The company contracts tens of thousands of farmers, supplies seed and agronomy support, and processes the flowers in plants in Kerala and Karnataka.
About 93% of standalone sales are exports. The US accounted for roughly 45% of FY2025 sales, and the top five customers for over 80% of revenue. Customers include Kemin Industries, which buys marigold oleoresin under a long-term exclusive supply agreement.
AVT combines a net-cash, A+-rated balance sheet with heavy working-capital intensity. After a weak FY2024–FY2025, earnings re-accelerated sharply in FY2026 and Q1 FY2027.
What the company does — company description
The company describes itself in its exchange profile and annual report as a manufacturer of plant-based extracts and natural ingredient solutions. It serves the food, beverage, animal nutrition and nutraceutical industries worldwide.
Exchange-filed descriptions list five primary business categories:
-
Marigold extracts for eye care, food colouring and poultry pigmentation
-
Spice oleoresins and oils for food colouring and flavouring
-
Value-added teas: decaffeinated teas and instant teas
-
Animal health and nutrition products
-
Agricultural crop inputs
Single reporting segment. For Ind AS 108 purposes the company reports one segment. The FY2026 NSE filing labels this segment "Solvent Extraction"; earlier annual reports call it "Food & Feed Ingredients from Natural Raw materials". Its business operations are described as being mainly in India, the USA, the UK and the UAE.
Independent characterisation
| End-market | AVT products used | Demand driver |
|---|---|---|
| Human nutraceuticals | Lutein/zeaxanthin from marigold | Eye health and ageing populations |
| Food and beverage colour and flavour | Paprika and capsicum oleoresins, marigold colour, spice oils | Clean-label replacement of synthetic dyes |
| Beverages | Instant tea for RTD/iced tea and premixes; decaffeinated tea | Consumer tea consumption formats |
| Animal nutrition | Poultry pigmentation (xanthophylls); botanical feed additives | Antibiotic-free production trends |
| Crop inputs | Not detailed | Small category |
| Personal care and cosmetics | Functional botanicals (antioxidant, UV-protection, melanin-inhibition, plant-based collagen-replacement actives, per the company's marketing descriptions) | Natural actives; scale not disclosed |
AVT is best understood as a contract-oriented B2B botanical extraction house. It is not a consumer brand. Its economics rest on four things:
(a) Raw-material access.
-
Marigold is the anchor crop. A 2020 company release cited about 35,000 acres under cultivation, about 100,000 metric tonnes of flowers a year and a network of about 30,000 farmers.
-
Spices and tea are bought largely at market prices.
(b) Extraction and refining capability.
- The core process is solvent extraction followed by refining, concentration, decaffeination and spray/freeze-drying for soluble tea.
(c) Embedded positions with a handful of global ingredient majors.
-
Long-term relationships with large customers drive repeat orders.
-
The exclusive marigold-oleoresin supply agreement with Kemin Industries (US) is the most important of these.
(d) Export pricing.
-
Revenue is earned predominantly in USD, EUR and GBP.
-
Costs are largely in INR, so currency movements feed directly into margins.
Revenue model. The revenue model is almost entirely product sales: bulk ingredients sold under supply agreements and purchase orders.
-
No subscription or licensing revenue is disclosed.
-
Some marigold supply is order-backed, meaning procurement is matched to customer orders. ICRA notes this limits inventory price risk.
-
Tolling or processing-service revenue, if any, is not separately disclosed.
Value chain position. AVT sits upstream-to-midstream:
-
It performs seed selection, breeding and contract cultivation for marigold.
-
It then extracts and refines the raw material into oleoresins, crude lutein esters and concentrated tea solubles.
-
Most output goes to formulators who make finished branded ingredients. For example, Kemin converts marigold extracts into branded lutein products for supplements and feed.
-
AVT therefore captures less of the end-value than branded ingredient companies, but carries agricultural and working-capital risk.
Customer types.
-
Global specialty ingredient companies
-
Flavour and colour houses
-
Beverage and tea companies (instant tea and decaffeinated tea buyers in the US, UK and Europe)
-
Animal-nutrition integrators and feed-additive distributors (US, Latin America, Middle East)
End-markets served.
Revenue mix by product category (indicative)
| Category (FY2025, % of revenue, ICRA indicative) | FY2025 |
|---|---|
| Marigold extracts (% of revenue, "less than") | 40 |
| Spice oils and oleoresins (% of revenue, "around") | 25 |
| Beverages — instant and decaf tea (% of revenue, "around") | 30 |
| Animal nutrition and others (% of revenue, residual, approximate) | 5 |
The company does not report product-category revenue in its segment note. The best public indication is ICRA's December 2025 rationale for FY2025:
-
Animal nutrition revenue grew more than 60% year on year in FY2025, from a small base (ICRA).
-
Marigold's share has fallen sharply over time. It was about 60% in FY2014 and about 40% in FY2020 (Outlook Business, citing company data).
Strategy
Stated strategic themes (annual-report MD&A, paraphrased)
-
Marigold remains the core. It is to stay a key segment for both revenue and profit, with the emphasis on sustaining growth through efficiency because of low marigold prices and renewed Chinese competition.
-
Value-added tea as the major growth engine. The aim is to consolidate the company's position as a key player in value-added tea. New soluble-tea offerings are being launched for instant-tea customers.
-
Specialty focus in spice oleoresins to protect margins rather than chase volume.
-
New segments. Animal health and nutrition, functional ingredients with cross-division applications, and new complementary product lines with nutritional applications.
-
Procurement discipline. Strategic buying and diversification of suppliers to stay cost-competitive. Farmer engagement (seeds, training) to secure marigold acreage against competing high-value crops.
Initiatives in the last 24 months
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Professional CEO appointment | Sep 2025 (confirmed for five years May 2026) | K. Nandakumar recruited from outside the industry. His track record is in industrial and consumer multinationals, with an emphasis on P&L, cash flow and new business models | In progress |
| Board refresh | Jun 2024 – Jun 2026 | New independent directors replacing those completing tenure; next-generation promoter family (Rahul Thomas, Siddharth Thomas) inducted | Completed |
| Working-capital limit enhancement | Dec 2025 | Rated cash-credit limit raised from ₹74.5 crore to ₹95 crore; non-fund-based limits to ₹15.33 crore | Completed |
| Capex programme | FY2026–FY2027 | ₹15–20 crore a year, internally funded (ICRA) | FY2026 capex about ₹23 crore |
| Animal nutrition geographic build-out | Ongoing | US, Mexico and UAE subsidiaries; segment grew more than 60% in FY2025 | Ongoing |
Cost programmes with quantified targets: none disclosed.
Medium-term financial targets / guidance: none publicly disclosed. The company does not hold earnings calls or publish investor presentations, based on the sources reviewed.
Products & Services
The company does not publish SKU-level pricing. Launch years for individual products are generally not disclosed. Brand names other than "Optim Health" are not disclosed in the sources reviewed.
Marigold extracts (about <40% of FY2025 revenue)
| Product | Description and specifications | Target customer | Notes |
|---|---|---|---|
| Food- and nutraceutical-grade marigold oleoresin / lutein esters | Solvent-extracted oleoresin from Tagetes erecta petals; source of lutein and zeaxanthin for eye-health supplements | Global nutraceutical ingredient majors, chiefly Kemin Industries under an exclusive long-term agreement | AVT describes itself as a leader in food-grade marigold oleoresin. Chinese producers compete aggressively on price |
| Marigold colour for food | Natural yellow-orange colourant | Food colour houses and food manufacturers | Clean-label colour replacement |
| Feed-grade marigold extract / xanthophylls | Poultry pigmentation (egg-yolk and broiler-skin colour) | Feed premix and additive companies | The company's original product line |
| Seed and cultivation programme | Seed selection, breeding and cultivation for proprietary marigold lines; farmer training | Internal (backward integration) | About 30,000 farmers and 35,000 acres (2020 data) |
Spice oils and oleoresins (about 25% of FY2025 revenue)
| Product | Description | Target customer |
|---|---|---|
| Paprika oleoresin | Natural red colour, standardised colour value | Food colour, meat and snacks seasoning |
| Capsicum oleoresin | Pungency (capsaicin) standardised extract | Seasoning and food manufacturers |
| Black pepper oleoresin and oil | Flavour (piperine), aroma | Flavour houses, seasoning blenders |
| Rosemary extract | Natural antioxidant (carnosic acid) for shelf-life extension | Food, feed and oils manufacturers |
| Other spice extracts | "New spice extract offerings" are referenced in management discussion; specific spices not disclosed | Flavour and colour houses |
Management's stated focus in spice oleoresins is on specialty products to protect margins, rather than commodity volume.
Value-added teas — beverages (about 30% of FY2025 revenue)
| Product | Description | Target customer |
|---|---|---|
| Instant / soluble tea (black and green) | Concentrated tea solids for RTD iced tea, premixes and vending; hot and cold blends | US, UK and European beverage brands and blenders |
| Decaffeinated tea | Decaffeination of black and green teas for bag and loose-leaf brands | UK/EU tea brands, via AVT Natural Europe |
| New soluble tea offerings | New grades launched for instant-tea customers (per MD&A); details not disclosed | Existing instant-tea customers |
| Tea infusions and natural flavouring blends | Referenced as growth drivers in MD&A | Premium-segment brands |
-
Management has repeatedly described value-added tea as a major growth area.
-
An earlier volume target was 1,000 MT of tea for FY2021.
Animal health and nutrition (small; grew more than 60% in FY2025)
| Product | Description | Target customer |
|---|---|---|
| Botanical feed additives | Plant-based solutions for animal health and performance. Product names not disclosed in sources reviewed | Poultry, swine and cattle integrators in North America, Latin America and the Middle East |
| Poultry pigmentation (crosses over with marigold) | Xanthophyll-based pigmenters | Feed mills |
The animal-nutrition line is marketed through AVT Natural North America Inc. (US), AVT Natural S.A. de C.V. (Mexico) and AVT Natural FZCO (UAE).
Other categories
| Product | Description | Status |
|---|---|---|
| Agricultural crop inputs | Listed as a business category in exchange profiles | Scale not disclosed |
| Functional botanicals and clean-label ingredients | Functional fibres, vegetable proteins; antioxidant, anti-inflammatory, melanin-inhibition, UV-protection and plant-collagen-replacement actives; natural colours | Marketed on the website; revenue not disclosed |
| Optim Health (domestic consumer supplements) | Launched Dec 2013 | Limited traction; small number of products available (Outlook Business) |
| De-oiled cake (legacy) | Soybean/oilseed meal, historical capacity 56,500 tpa | Historical. |
Financial Detail
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment revenue — single segment (INR Cr, consolidated) | 517 | 559 | 713 |
Segment EBITDA (INR Cr, consolidated operating profit) | 79 | 73 | 90 |
Segment EBITDA margin (%) | 15 | 13 | 13 |
Segment PBT (INR Cr) | 71 | 63 | 83 |
Revenue growth year on year (%) | -11.2 | 8.0 | 27.6 |
Contribution to total revenue (%) | 100 | 100 | 100 |
Group Entities
| Entity | Country | Ownership | Function |
|---|---|---|---|
AVT Natural Products Ltd (parent) | India | Listed | Manufacturing, R&D, farmer network, export sales |
AVT Natural Europe Ltd (formerly AVT Tea Services Ltd) | United Kingdom | 100% | Marketing arm for decaffeinated and instant tea; European sales. FY2020: sales ₹59 crore, PAT ₹1.15 crore |
AVT Natural North America Inc. | USA | 100% (through AVT Natural Europe) | Sales and marketing of value-added teas, animal nutrition and natural extracts in North America |
AVT Tea Services North America LLC | USA | — | US tea services/marketing |
AVT Natural S.A. de C.V. | Mexico | 100% | Animal-nutrition products for Latin America. FY2020: sales ₹2.17 crore, loss ₹3.33 crore |
AVT Natural FZCO | Dubai, UAE | 100% | Middle East / Africa trading and marketing hub (scope not detailed) |
Segment Revenue
| Metric (INR Cr, FY2026) | Standalone | Consolidated | Subsidiaries (derived) |
|---|---|---|---|
Revenue from operations | 683.8 | 713.2 | 29.4 |
Profit after tax | 53.9 | 64.8 | 10.9 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 559 | 582 | 517 | 559 | 713 |
Revenue growth (%) | 15.3 | 4.1 | -11.2 | 8.0 | 27.6 |
Cost of revenue (INR Cr, StockAnalysis) | 270.4 | 244.8 | 234.2 | 259.3 | 347.0 |
Gross profit (INR Cr, StockAnalysis) | 289.0 | 337.4 | 283.1 | 299.6 | 366.2 |
EBITDA / operating profit (INR Cr, Screener) | 106 | 121 | 79 | 73 | 90 |
Depreciation (INR Cr) | 14 | 13 | 14 | 14 | 11 |
Operating income / EBIT before other income (INR Cr, StockAnalysis) | 91.3 | 107.6 | 65.5 | 59.3 | 78.2 |
Other income (INR Cr) | 10 | 2 | 13 | 13 | 14 |
Interest expense (INR Cr, Screener) | 5 | 5 | 7 | 9 | 9 |
Pre-tax income (INR Cr) | 97 | 105 | 71 | 63 | 83 |
Effective tax rate (%) | 25 | 26 | 25 | 24 | 22 |
Net income (INR Cr) | 72.9 | 77.4 | 53.3 | 48.2 | 64.8 |
EPS basic (INR) | 4.78 | 5.08 | 3.50 | 3.17 | 4.26 |
EPS diluted (INR) | 4.78 | 5.08 | 3.50 | 3.17 | 4.26 |
Dividend payout (%) | 21 | 20 | 23 | 22 | 19 |
DPS (₹, derived = payout × EPS; FY2026 reported) | 1.00 | 1.02 | 0.81 | 0.70 | 0.80 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 51.7 | 58.0 | 54.7 | 53.6 | 51.4 |
EBITDA margin (%) | 19.0 | 20.8 | 15.3 | 13.1 | 12.6 |
Operating (EBIT) margin (%) | 16.3 | 18.5 | 12.7 | 10.6 | 11.0 |
Net margin (%) | 13.0 | 13.3 | 10.3 | 8.6 | 9.1 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 132.4 | 160 | 194 | 226 | 241.2 |
EBITDA (INR Cr) | 16 | 15 | 23 | 36 | 39.9 |
OPM (%) | 12 | 9 | 12 | 16 | 16.6 |
PBT (INR Cr) | 14.85 | 15.75 | 21.64 | 30.41 | 39.05 |
PAT (INR Cr) | 12.12 | 13.29 | 17.37 | 22.02 | 31.10 |
EPS (INR) | 0.80 | 0.87 | 1.14 | 1.45 | 2.04 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 449 | 522 | 598 | 747 | 846 |
Cash and equivalents (INR Cr, StockAnalysis) | 14.3 | 20.1 | 25.8 | 33.6 | 30.9 |
Cash + short-term investments incl. liquid funds (INR Cr) | 42.6 | 78.6 | 153.5 | 170.0 | 147.2 |
Investments on balance sheet (INR Cr, Screener) | 28 | 58 | 127 | 136 | 116 |
Trade receivables (INR Cr) | 102.1 | 121.4 | 110.0 | 156.4 | 240.4 |
Inventory (INR Cr) | 183.3 | 212.0 | 221.1 | 293.7 | 320.6 |
Total current assets (INR Cr) | 362.3 | 440.6 | 510.6 | 663.0 | 756.7 |
Net fixed assets (INR Cr) | 82 | 78 | 82 | 72 | 81 |
Total borrowings (INR Cr) | 25 | 37 | 43 | 113 | 114 |
Net debt (INR Cr; negative = net cash, StockAnalysis) | -17.4 | -41.6 | -110.9 | -57.3 | -33.6 |
Share capital (INR Cr) | 15.2 | 15.2 | 15.2 | 15.2 | 15.2 |
Reserves (INR Cr) | 354 | 415 | 454 | 491 | 544 |
Shareholders' equity (INR Cr) | 369 | 430 | 469 | 506 | 559 |
Book value per share (₹, derived) | 24.2 | 28.3 | 30.8 | 33.2 | 36.7 |
Other liabilities (INR Cr) | 55 | 55 | 86 | 128 | 173 |
Net working capital (INR Cr, derived = current assets – borrowings – other liabilities, approximate) | 282 | 349 | 382 | 422 | 470 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 74.4 | 51.2 | 98.5 | -32.5 | 12.0 |
Capex (INR Cr, derived = OCF – FCF, StockAnalysis) | 8.0 | 8.0 | 12.5 | 9.2 | 23.4 |
Free cash flow (INR Cr) | 66.4 | 43.2 | 86.1 | -41.7 | -11.4 |
Investing cash flow (INR Cr) | -28.9 | -36.8 | -73.0 | -9.4 | 1.3 |
Financing cash flow (INR Cr) | -45.0 | -8.5 | -20.2 | 50.0 | -16.0 |
CFO / EBITDA (%, Screener, pre-tax basis) | 95 | 64 | 149 | -25 | 33 |
Cash interest paid (INR Cr) | 4.2 | 5.1 | 6.8 | 9.2 | 9.2 |
Cash taxes paid (INR Cr) | 26.1 | 26.5 | 19.9 | 14.1 | 18.0 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%, derived on average equity) | 21.5 | 19.4 | 11.9 | 9.9 | 12.2 |
ROA (%, derived on average assets) | 16.7 | 15.9 | 9.5 | 7.2 | 8.1 |
ROCE (%, Screener) | 27 | 25 | 16 | 13 | 14 |
Current ratio (x, derived approximation) | 4.5 | 4.8 | 4.0 | 2.8 | 2.6 |
Debt / equity (x) | 0.07 | 0.09 | 0.09 | 0.22 | 0.20 |
Net debt / EBITDA (x; negative = net cash) | -0.16 | -0.34 | -1.40 | -0.78 | -0.37 |
Interest coverage (x, EBITDA / interest, derived) | 21.2 | 24.2 | 11.3 | 8.1 | 10.0 |
Asset turnover (x, revenue / average assets) | 1.28 | 1.20 | 0.92 | 0.83 | 0.90 |
Debtor days | 67 | 76 | 78 | 102 | 123 |
Inventory days | 263 | 342 | 365 | 431 | 348 |
Payable days | 45 | 44 | 97 | 146 | 143 |
Cash conversion cycle (days) | 284 | 373 | 346 | 388 | 327 |
Working-capital days | 163 | 177 | 172 | 171 | 167 |
Revenue by Region (%)
| Metric | FY2020 | FY2025 |
|---|---|---|
Exports (% of standalone revenue) | 95 | 93 |
Domestic India (% of revenue) | 5 | 7 |
United States (% of revenue, ICRA, approximate) | — | 45 |
Valuation Snapshot
| Metric | Value | Date / source |
|---|---|---|
Last close (NSE) | ₹99.70 | 19 Oct 2026 (Screener) |
Market capitalisation | ₹1,519 crore | 19 Oct 2026 |
52-week high / low | ₹108 / ₹53.3 | Screener |
All-time high / low | ₹135.70 / ₹4.89 | ICICI Direct |
1-year price change | +46% | Screener |
3-year price CAGR | 3% | Screener |
5-year price CAGR | 3% | Screener |
10-year price CAGR | 10% | Screener |
Shareholders | 45,138 | Sep 2026 |
Share Price
| Metric | Mar-2025 | Dec-2025 | Mar-2026 | Jul-2026 | Oct-2026 |
|---|---|---|---|---|---|
Share price (₹, approximate) | 70 | 68 | 59 | 70 | 100 |
Valuation Multiples
| Multiple | AVT | Basis |
|---|---|---|
P/E (TTM) | 18.1x | Price ₹99.7 / TTM EPS ₹5.50 |
P/B | 2.71x | Book value ₹36.7 (Mar 2026) |
EV/EBITDA (TTM, derived) | about 13.1x | EV about ₹1,485 crore (market cap ₹1,519 crore less net cash ₹34 crore) / TTM EBITDA ₹113.6 crore |
EV/Sales (TTM, derived) | about 1.8x | TTM revenue ₹822 crore |
Dividend yield | 0.80% | DPS ₹0.80 |
Sector / industry P/E | about 35–47x | Univest and Aaj Tak aggregators (FMCG classification). Not a like-for-like peer set |
Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
DPS (₹; FY2026 reported, earlier years derived from payout) | 1.00 | 1.02 | 0.81 | 0.70 | 0.80 |
Payout ratio (%) | 21 | 20 | 23 | 22 | 19 |
Long-term by Date
| Date | Long-term | Short-term | Rated amount (INR Cr) |
|---|---|---|---|
7 Jan 2019 | A (Stable) | A1 | about 43 |
7 Jan 2020 | A (Stable) | A1 | about 99 |
11 Jan 2021 | A+ (Stable) — upgraded | A1 | — |
31 Mar 2022 | A+ (Stable) | A1+ — upgraded | — |
12 Jun 2023 | A+ (Stable) | A1+ | 98.88 |
30 Sep 2024 | A+ (Stable) | A1+ | 98.88 |
22 Dec 2025 | A+ (Stable) | A1+ | 114.48 |
Analyst Conclusions
Management guidance and consensus
-
No quantitative guidance is published and there is no sell-side consensus.
-
ICRA's Dec 2025 view expected stable performance and no material OPM improvement in the near to medium term, with capex of ₹15–20 crore a year. That margin view has since been exceeded: OPM was about 16–17% in Q4 FY2026 and Q1 FY2027.
Run-rate arithmetic (not a forecast): annualising Q1 FY2027 gives revenue of about ₹965 crore and PAT of about ₹124 crore. Seasonality makes simple annualisation unreliable. Q1 has historically been the weakest quarter, but Q1 FY2027 may include some pre-buying.
Bull case
-
Operating leverage is real and visible. Revenue grew about 82% while EBITDA grew about 151% in Q1 FY2027, on a fixed-asset base of only about ₹81 crore. If revenue holds above ₹200 crore a quarter, ROCE can move toward ICRA's 20% upgrade threshold.
-
Structural demand tailwinds in natural colours (US synthetic-dye phase-down), lutein (ageing populations) and RTD tea. Tariff relief on beverages from November 2025 adds to these.
-
Valuation still undemanding. About 18x TTM P/E and about 13x EV/EBITDA for an A+-rated, net-cash company with a contracted offtake partner. Negligible institutional ownership leaves room for discovery if disclosure improves under a professional CEO.
Bear case
-
Cash does not follow profit. Free cash flow was negative in FY2025 and FY2026 even as PAT rose. Debtor days rose to 123 and the cash conversion cycle exceeds 300 days. Reported earnings growth may be partly financed by customer credit.
-
Concentration risk is binary. With the top five customers above 80% of revenue and the US at about 45%, losing or repricing a single contract — Kemin in particular — or a fresh US tariff could reverse the recovery. Chinese marigold pricing remains a structural cap.
-
Cyclicality and base effects. Q1 FY2027 was compared against a weak base, and FY2024 showed that a poor crop season can cut revenue by double digits. The stock's 46% one-year rise, with repeated exchange volume enquiries, already prices in a good deal of the improvement.
Catalysts and monitorables (next 12 months)
| Item | Expected timing | What to watch |
|---|---|---|
| Q2 FY2027 results | About mid-November 2026 (trading window closed 25 Sep) | Whether revenue stays above ₹200 crore and OPM above 15%; receivables trend |
| H1 FY2027 balance sheet | With Q2 results | Operating cash flow, inventory and debtor days |
| Marigold crop season (Kharif / Rabi 2026–27) | Q3–Q4 FY2027 | Flower availability and procurement cost |
| US trade policy | Ongoing | Tariffs on non-beverage botanicals and colours |
| INR/USD | Ongoing | Rupee appreciation risk to margins |
| ICRA surveillance | About Dec 2026 | Possible positive outlook or upgrade if ROCE above 20% |
| CEO strategy articulation | FY2027 | First investor communication, new markets, capex plans |
| Q4 FY2027 / FY2027 results | May 2027 | Full-year cash conversion; dividend step-up |
Analyst verdict
AVT Natural Products enters late 2026 at its strongest operating point in its 40-year history. Quarterly revenue is above ₹240 crore, margins have recovered to about 16–17%, and TTM PAT is about ₹84 crore. Leadership has also changed: a professional chief executive now leads the company, with a five-year mandate and a background in multinational P&L and cash management. The franchise underneath is genuine. It rests on decades of marigold contract farming, an exclusive offtake with Kemin, a three-leg product portfolio that has broadened beyond marigold, and an A+-rated, net-cash balance sheet. At about 18x trailing earnings and about 13x EV/EBITDA, the market does not yet value AVT as a natural-ingredients compounder.
The case for a durable re-rating, however, depends on a variable the income statement does not show: cash conversion.
-
Over five years the company converted under half of its EBITDA into operating cash flow.
-
In FY2026, its best year, free cash flow was negative because receivables grew by about ₹84 crore.
-
Customer concentration (top five customers above 80%) and US exposure (about 45%) mean the recent revenue surge rests on a small number of buying decisions. The Q1 FY2027 growth rate is unlikely to be repeated once the base normalises.
Our synthesis is that AVT has moved from a value trap (FY2023–FY2025: shrinking returns, flat stock) to an earnings-recovery story with an unproven cash leg. The three things that would confirm a structural, rather than cyclical, improvement are:
-
Positive free cash flow in H1 FY2027.
-
Debtor days back below 100.
-
Margins held above 15% through a full crop cycle.
If all three are met, an ICRA upgrade and wider institutional interest become plausible. If receivables and inventory keep absorbing the profit, the stock's 2026 rally will look like another momentum episode of the kind seen in 2021–2023.
Stance: Constructive on fundamentals. Cautious on near-term entry after a 46% rally. The H1 FY2027 cash-flow statement is the decisive monitorable.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background |
|---|---|---|---|
K. Nandakumar | Chief Executive Officer; designated Manager & CEO (KMP) for five years from 28 May 2026 | CEO since 1 Sep 2025 | 30+ years across Philips, GE, 3M, Honeywell and TVS Rubber (most recently CEO, TVS Rubber). Focus on new markets, business models, P&L and cash-flow management. Age and education not disclosed in sources reviewed |
M.N. Satheesh Kumar | Manager (Key Managerial Personnel) | 28 May 2025 – 27 May 2026 (one-year term approved at 39th AGM); succeeded by the CEO as Manager | Long-serving executive. |
P. Mahadevan | Company Secretary & Compliance Officer | Current | Signs exchange filings (e.g. Reg. 74(5) certificate, Apr 2026) |
CFO | Chief Financial Officer | — | — |
Board of Directors
| Name | Role | Notes |
|---|---|---|
Ajit Thomas | Chairman (promoter); Non-Executive | Chairman of the A.V. Thomas Group; holds 1.00% directly. |
Rahul Thomas (DIN 09762551) | Non-Executive Director (promoter family) | Appointed 12 Jun 2024; MBA, degree in Economics; retired by rotation and re-appointed at 40th AGM (17 Aug 2026) |
Siddharth Thomas | Non-Executive Director (promoter family) | Additional Director from 9 Jun 2026; regularised at 40th AGM |
Kavitha Vijay | Independent Director | Re-appointed for a second five-year term from 23 Sep 2025 |
A.D. Bopana | Former Independent Director | Retired 25 Aug 2025; committees reconstituted 26 Aug 2025 |
Other independent directors | Independent | — |
Major Shareholders
| Holder | Shares | % |
|---|---|---|
Neelamalai Agro Industries Ltd (promoter) | 60,913,600 | 40.00 |
Other promoter-group bodies corporate (combined) | about 51.5 million | about 33.85 |
Ajit Thomas (promoter, individual) | 1,522,840 | 1.00 |
Other promoter individuals / HUF (2 holders) | 233,000 | 0.15 |
Total promoter and promoter group (6 holders) | 114,212,975 | 75.00 |
Investor Education & Protection Fund | — | about 1.17 |
Vistra ITCL (India) Ltd (largest named public holder) | — | about 1.01 |
Foreign portfolio investors (4 FIIs) | — | 0.03 (0.04 Sep 2026) |
Domestic institutions (incl. mutual funds: nil) | — | 0.02 |
Individuals and other public | — | about 22.8 |
Total public (52,201 holders at Mar 2026; 45,138 at Sep 2026) | 38,071,025 | 25.00 |
Competitive Landscape
Competitors by Segment
| Category | Competitor | HQ | Positioning vs AVT |
|---|---|---|---|
Marigold / lutein | Chinese marigold-extract producers, e.g. Chenguang Biotech Group | China | Largest global capacity in plant extracts; aggressive pricing, described by AVT's management as subsidy-assisted. The main threat to marigold margins |
Marigold / lutein | Synthite Industries (private) | India (Kerala) | World's largest spice-oleoresin maker; also in marigold. Much larger scale |
Marigold / lutein, spice | Plant Lipids (private) | India (Kerala) | Direct spice-oleoresin competitor |
Marigold / lutein, nutraceutical | OmniActive Health Technologies (private) | India | Branded lutein (Lutemax); higher value-add |
Marigold / lutein, nutraceutical | DSM-Firmenich, BASF | Netherlands/Switzerland, Germany | Synthetic or formulated lutein / carotenoids |
Spice oleoresins | Mane Kancor (Mane group) | India / France | Spice extracts, flavours |
Spice oleoresins | Akay Natural Ingredients (private) | India | Spice extracts, curcumin |
Spice oleoresins | Givaudan (Naturex division) | Switzerland | Global natural extracts leader |
Natural colours | Oterra; Sensient Technologies (Colours group) | Denmark; USA | Global natural-colour formulators that compete for and buy oleoresins |
Instant / decaf tea | Finlays (Swire group) | UK | Global leader in tea extracts and soluble tea |
Instant / decaf tea | Tata Consumer Products (instant tea operations) | India | Integrated tea major with extraction capacity |
Instant / decaf tea | Martin Bauer Group (private) | Germany | Botanical and tea extracts |
Botanical animal nutrition | Delacon (now part of Cargill), Phytobiotics (private), Natural Remedies (private) | Austria/USA; Germany; India | Phytogenic feed additives |
Botanical animal nutrition | Kemin (feed division) | USA | Kemin is both customer and potential competitor |
Peer Comparison FY2026
| Company | Latest FY revenue | Revenue growth | EBITDA margin | Comment |
|---|---|---|---|---|
AVT Natural Products (FY2026, INR Cr) | 713 | +27.6% | 12.6% (TTM about 13.8%) | Verified |
Sensient Technologies (2024, USD Mn, approximate) | about 1,560 | low single-digit | — | Colours segment is a direct comparable for natural colours |
Givaudan (2024, CHF Mn, approximate) | about 7,400 | high single-digit | — | Taste & Wellbeing includes Naturex extracts |
Tata Consumer Products (FY2025, INR Cr, approximate) | about 17,600 | — | — | Instant-tea operations are a small part |
Recent Developments
There were no layoffs, litigation or regulatory enforcement actions in this period beyond the minor exchange fines noted.



